miR-302a-3p suppresses melanoma cell progression via targeting METTL3

Chang, Xiao; Lin, Ying‐Chu; Bai, Lina; Zhu, Wei

doi:10.1080/1120009x.2021.1953886

Cited by 11 publications

(6 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…found that UCK2 overexpression was regulated by m 6 A-METTL3 axis in melanoma metastasis ( 53 ); Chang et al. proposed that miR-302a-3p targets and suppresses the expression of METTL3 to inhibit melanoma cell progression ( 54 ). In accordance with this, elevated METTL3 expression was detected in human melanoma cell lines, which led to increased m 6 A activity, colony formation, and invasion of melanoma cells through MMP2 and N-cadherin accumulation ( 55 ).…”

Section: Discussionmentioning

confidence: 99%

m6A Methyltransferase METTL3 Promotes the Progression of Primary Acral Melanoma via Mediating TXNDC5 Methylation

et al. 2022

View full text Add to dashboard Cite

m6A modification is one of the most important post-transcriptional modifications in RNA and plays an important role in promoting translation or decay of RNAs. The role of m6A modifications has been highlighted by increasing evidence in various cancers, which, however, is rarely explored in acral melanoma. Here, we demonstrated that m6A level was highly elevated in acral melanoma tissues, along with the expression of METTL3, one of the most important m6A methyltransferase. Besides, higher expression of METTL3 messenger RNA (mRNA) correlated with a higher stage in primary acral melanoma patients. Knockdown of METTL3 decreased global m6A level in melanoma cells. Furthermore, METTL3 knockdown suppressed the proliferation, migration, and invasion of melanoma cells. In METTL3 knockdown xenograft mouse models, we observed decreased volumes and weights of melanoma tissues. Mechanistically, we found that METTL3 regulates certain m6A-methylated transcripts, thioredoxin domain containing protein 5 (TXNDC5), with the confirmation of RNA-seq, MeRIP-seq, and Western blot. These data suggest that METTL3 may play a key role in the progression of acral melanoma, and targeting the m6A dependent-METTL3 signaling pathway may serve as a promising therapeutic strategy for management of patients of acral melanomas.

show abstract

Section: Discussionmentioning

confidence: 99%

m6A Methyltransferase METTL3 Promotes the Progression of Primary Acral Melanoma via Mediating TXNDC5 Methylation

et al. 2022

View full text Add to dashboard Cite

show abstract

“…A study found that METTL3 induced UCK2 m6A hypermethylation and promoted the metastasis of melanoma cells through the WNT/β-catenin pathway [ 290 ]. METTL3 may be involved in the proliferation, invasion, migration and resistance of melanoma cells [ 291 , 292 ]. ALKBH5 increases the stability and expression of FOXM1 mRNA via m6A demethylation and induce the epithelial-mesenchymal transition (EMT) to promote melanoma metastasis [ 110 ].…”

Section: M6a and Cancersmentioning

confidence: 99%

Role of m6A writers, erasers and readers in cancer

Fang

Mei

et al. 2022

Exp Hematol Oncol

View full text Add to dashboard Cite

The N(6)-methyladenosine (m6A) modification is the most pervasive modification of human RNAs. In recent years, an increasing number of studies have suggested that m6A likely plays important roles in cancers. Many studies have demonstrated that m6A is involved in the biological functions of cancer cells, such as proliferation, invasion, metastasis, and drug resistance. In addition, m6A is closely related to the prognosis of cancer patients. In this review, we highlight recent advances in understanding the function of m6A in various cancers. We emphasize the importance of m6A to cancer progression and look forward to describe future research directions.

show abstract

“…MiR-302a-3p, by blocking the expression of METTL3, reduced tumor growth metastasis and other malignant behavior features. The study found a new target, the miR-302a-3p/METTL3 axis, for future melanoma therapies [ 96 ].…”

Section: Examples Of Melanoma-related Micrornasmentioning

confidence: 99%

MicroRNA as a Diagnostic Tool, Therapeutic Target and Potential Biomarker in Cutaneous Malignant Melanoma Detection—Narrative Review

Poniewierska-Baran

Zadroga

Danilyan

et al. 2023

IJMS

View full text Add to dashboard Cite

Melanoma is the most serious type of skin cancer, causing a large majority of deaths but accounting for only ~1% of all skin cancer cases. The worldwide incidence of malignant melanoma is increasing, causing a serious socio-economic problem. Melanoma is diagnosed mainly in young and middle-aged people, which distinguishes it from other solid tumors detected mainly in mature people. The early detection of cutaneous malignant melanoma (CMM) remains a priority and it is a key factor limiting mortality. Doctors and scientists around the world want to improve the quality of diagnosis and treatment, and are constantly looking for new, promising opportunities, including the use of microRNAs (miRNAs), to fight melanoma cancer. This article reviews miRNA as a potential biomarker and diagnostics tool as a therapeutic drugs in CMM treatment. We also present a review of the current clinical trials being carried out worldwide, in which miRNAs are a target for melanoma treatment.

show abstract

miR-302a-3p suppresses melanoma cell progression via targeting METTL3

Cited by 11 publications

References 32 publications

m6A Methyltransferase METTL3 Promotes the Progression of Primary Acral Melanoma via Mediating TXNDC5 Methylation

m6A Methyltransferase METTL3 Promotes the Progression of Primary Acral Melanoma via Mediating TXNDC5 Methylation

Role of m6A writers, erasers and readers in cancer

MicroRNA as a Diagnostic Tool, Therapeutic Target and Potential Biomarker in Cutaneous Malignant Melanoma Detection—Narrative Review

Contact Info

Product

Resources

About